AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
May 16
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 17, 2025
DataAggregated Company Financials
Companies565
- 7D3.7%
- 3M-10.1%
- 1Y-14.2%
- YTD-7.0%
In the last week, the Biotech industry is up 3.7%, with Regeneron Pharmaceuticals leading the way, up 13%. In the same time, Halozyme Therapeutics was down 21%. In contrast, the industry has lost 14% in the last 12 months. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 17 May 2025 | US$884.2b | US$155.9b | -US$24,431,976,921.60 | 16.3x | -36.2x | 5.7x |
| Mon, 14 Apr 2025 | US$740.3b | US$119.2b | -US$36,459,506,079.34 | 19.8x | -20.3x | 6.2x |
| Wed, 12 Mar 2025 | US$844.0b | US$118.8b | -US$37,363,246,365.87 | 17.4x | -22.6x | 7.1x |
| Fri, 07 Feb 2025 | US$871.2b | US$117.2b | -US$30,910,657,601.72 | 17.5x | -28.2x | 7.4x |
| Sun, 05 Jan 2025 | US$980.2b | US$149.6b | -US$26,354,792,434.12 | 17x | -37.2x | 6.6x |
| Tue, 03 Dec 2024 | US$1.0t | US$150.0b | -US$26,582,450,296.63 | 16.6x | -39.2x | 6.9x |
| Thu, 31 Oct 2024 | US$894.4b | US$113.6b | -US$35,812,239,881.01 | 18.6x | -25x | 7.9x |
| Sat, 28 Sep 2024 | US$891.6b | US$113.2b | -US$35,989,290,216.71 | 21.3x | -24.8x | 7.9x |
| Mon, 26 Aug 2024 | US$908.6b | US$113.2b | -US$35,874,993,723.21 | 23.6x | -25.3x | 8x |
| Wed, 24 Jul 2024 | US$1.2t | US$164.5b | -US$28,071,798,540.98 | 28.8x | -43x | 7.3x |
| Fri, 21 Jun 2024 | US$1.1t | US$164.4b | -US$27,914,641,228.07 | 27.5x | -40.7x | 6.9x |
| Sun, 19 May 2024 | US$1.1t | US$164.6b | -US$26,835,738,666.64 | 23.9x | -42.8x | 7x |
| Tue, 16 Apr 2024 | US$1.1t | US$164.3b | -US$23,399,965,626.52 | 21.4x | -46.9x | 6.7x |
| Thu, 14 Mar 2024 | US$1.2t | US$167.4b | -US$22,015,596,093.89 | 18.8x | -54.1x | 7.1x |
| Sat, 10 Feb 2024 | US$1.2t | US$169.3b | -US$26,269,121,791.87 | 19.8x | -44.2x | 6.9x |
| Mon, 08 Jan 2024 | US$1.4t | US$204.8b | -US$22,501,061,722.00 | 20.5x | -63.1x | 6.9x |
| Wed, 06 Dec 2023 | US$1.3t | US$204.6b | -US$22,051,652,521.00 | 19.3x | -57.6x | 6.2x |
| Fri, 03 Nov 2023 | US$1.2t | US$206.8b | -US$20,351,431,827.00 | 17.2x | -59.7x | 5.9x |
| Sun, 01 Oct 2023 | US$1.3t | US$207.4b | -US$13,122,605,528.00 | 17.1x | -95.8x | 6.1x |
| Tue, 29 Aug 2023 | US$1.3t | US$207.6b | -US$12,455,656,838.00 | 17.5x | -102.5x | 6.1x |
| Thu, 27 Jul 2023 | US$1.1t | US$186.8b | -US$16,232,873,446.00 | 14.3x | -69.8x | 6.1x |
| Sat, 24 Jun 2023 | US$1.1t | US$186.2b | -US$16,162,116,001.00 | 13.6x | -70.3x | 6.1x |
| Mon, 22 May 2023 | US$1.2t | US$186.0b | -US$15,898,792,960.00 | 13x | -72.5x | 6.2x |
| Wed, 19 Apr 2023 | US$1.2t | US$198.4b | -US$3,275,992,798.00 | 13.4x | -358.6x | 5.9x |
| Fri, 17 Mar 2023 | US$1.1t | US$199.1b | -US$4,760,446,272.00 | 13.3x | -238.2x | 5.7x |
| Sun, 12 Feb 2023 | US$1.2t | US$202.7b | -US$201,937,721.00 | 16.4x | -5723.2x | 5.7x |
| Tue, 10 Jan 2023 | US$1.1t | US$203.5b | US$1.7b | 13.8x | 685.5x | 5.6x |
| Thu, 08 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 14.9x | 839.9x | 5.7x |
| Sat, 05 Nov 2022 | US$1.1t | US$204.6b | US$3.6b | 14.2x | 299.5x | 5.3x |
| Mon, 03 Oct 2022 | US$1.0t | US$206.2b | US$5.5b | 14.9x | 187.1x | 4.9x |
| Wed, 31 Aug 2022 | US$1.0t | US$206.3b | US$7.3b | 14.4x | 141.1x | 5x |
| Fri, 29 Jul 2022 | US$1.1t | US$211.2b | US$11.2b | 16.4x | 96.6x | 5.1x |
| Sun, 26 Jun 2022 | US$1.1t | US$212.4b | US$11.1b | 15.4x | 95.1x | 4.9x |
| Tue, 24 May 2022 | US$1.0t | US$212.6b | US$11.1b | 14.9x | 90.9x | 4.7x |
Price to Earnings Ratio
90.9x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 5.34% | |
| Healthcare | 0.73% | |
| Biotech | 3.68% | |
| Biotech | 3.68% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | US$594.32 | 12.6% +US$7.0b | -39.5% | PE14x | |
| GILD Gilead Sciences | US$102.50 | 5.8% +US$7.0b | 51.4% | PE21.4x | |
| ALNY Alnylam Pharmaceuticals | US$285.31 | 13.6% +US$4.5b | 91.0% | PS15.8x | |
| AMGN Amgen | US$272.41 | 2.5% +US$3.5b | -12.8% | PE24.7x | |
| VRTX Vertex Pharmaceuticals | US$438.65 | 3.2% +US$3.5b | -1.5% | PS10.1x |
